ENSURING PHARMACOLOGICAL SAFETY IN CLINICAL PRACTICE: DRUG–DRUG INTERACTIONS

O`ktamova N.B.

Tashkent City Alfraganus University Faculty of Medicine, General Medicine Program 3rd-year Student

Boymuratov F.T.

Tashkent City Alfraganus University Faculty of Medicine, Department of Pharmacy and Chemistry Associate

Keywords: Drug–drug interaction; pharmacological safety; pharmacokinetics; pharmacodynamics; adverse effects; clinical pharmacology; rational pharmacotherapy.

---

Abstract

Abstract: Drug–drug interactions (DDIs) represent one of the most critical challenges in clinical pharmacology and patient safety. The simultaneous use of multiple medications can alter pharmacokinetic and pharmacodynamic properties, leading to reduced efficacy or increased toxicity. This article explores the mechanisms of DDIs, their clinical implications, and strategies to predict, prevent, and manage adverse interactions in medical practice. A focus is given to the importance of individualized therapy, rational prescribing, and the implementation of digital pharmacovigilance systems in modern healthcare. The study emphasizes the role of continuous education among healthcare professionals in recognizing and minimizing DDI risks to enhance patient safety and therapeutic outcomes.

---

References

1. Tatro DS. Drug Interaction Facts 2023: The Authority on Drug Interactions. Facts and Comparisons, 2023.

2. Stockley IH. Stockley’s Drug Interactions. 12th ed. Pharmaceutical Press, 2022.

3. Horn JR, Hansten PD. “Drug–drug interactions: Mechanisms and clinical implications.” American Journal of Health-System Pharmacy. 2019; 76(16):1189–1201.

4. U.S. Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Silver Spring, MD: FDA, 2023.

5. World Health Organization. Medication Safety in Polypharmacy: Technical Report. Geneva: WHO, 2019.

6. Juurlink DN. “Drug interactions and polypharmacy in the elderly.” Canadian Medical Association Journal. 2019; 191(23):E627–E628.

7. Lee CR, Goldstein JA, Pieper JA. “Cytochrome P450 2C9 polymorphisms: Impact on warfarin therapy.” Clinical Pharmacokinetics. 2002; 41(7): 481–494.

8. Payne TH, et al. “Using electronic health record–based decision support to reduce adverse drug events.” Journal of the American Medical Informatics Association. 2018; 25(10):1264–1272.

9. European Medicines Agency (EMA). Guideline on the Investigation of Drug Interactions. London: EMA, 2020.

10. Bahar MA, et al. “Trends in drug–drug interactions: A review of recent studies.” Frontiers in Pharmacology. 2021; 12:665222.